Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

Published On: July 30th, 2024Categories: Oncology Industry News

We are pleased to share with you that on July 25th, 2024, the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of Myelodysplastic Syndromes (MDS) to recommend RYTELO™️ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS.